

## DAFTAR PUSTAKA

- Abraldes, J.G., Albillos, A., Bañares, R., Turnes, J., González, R., García-Pagán, J.C., dkk., 2009. Simvastatin Lowers Portal Pressure in Patients with Cirrhosis and Portal Hypertension: a Randomized Controlled Trial. *Gastroenterology*, **136**: 1651–1658.
- Abraldes, J.G., Villanueva, C., Aracil, C., Turnes, J., Hernandez-Guerra, M., Genesca, J., dkk., 2016. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. *Gastroenterology*, **150**: 1160-1170.e3.
- Armitage, J., 2007. The Safety of Statins in Clinical Practice. *Lancet (London, England)*, **370**: 1781–1790.
- Asrani, S.K., Devarbhavi, H., Eaton, J., dan Kamath, P.S., 2019. Burden of Liver Diseases in The World. *Journal of Hepatology*, **70**: 151–171.
- Bang, U.C., Benfield, T., Hyldstrup, L., Jensen, J.-E.B., dan Bendtsen, F., 2016. Effect of Propranolol on Survival in Patients with Decompensated Cirrhosis: a Nationwide Study Based Danish Patient Registers. *Liver International: Official Journal of the International Association for the Study of the Liver*, **36**: 1304–1312.
- Bansal, M.B. dan Friedman, S.L., 2018. Hepatic Fibrogenesis, dalam: Dooley, J.S., Lok, A.S.F., Garcia-Tsao, G., dan Pinzani, M. (Editor), *Sherlock's Diseases of the Liver and Biliary System*. John Wiley & Sons Ltd, Oxford, UK, hal. 82–92.
- Bełtowski, J., Wójcicka, G., dan Jamroz-Wisniewska, A., 2009. Adverse Effects of Statins - Mechanisms and Consequences. *Current Drug Safety*, **4**: 209–228.
- Birkett, M.A. dan Day, S.J., 1994. Internal Pilot Studies for Estimating Sample Size. *Statistics in Medicine*, **13**: 2455–2463.
- Bosch, J. dan Berzigotti, A., 2018. Portal Hypertension in Cirrhosis, dalam: Dooley, J.S., Lok, A.S.F., Garcia-Tsao, G., dan Pinzani, M. (Editor), *Sherlock's Diseases of the Liver and Biliary System*. John Wiley & Sons Ltd, Oxford, UK, hal. 180–208.
- Cai, G., Chen, Y., Li, L., Zhou, B., Hu, C., Yu, Y., dkk., 2018. Meta-Analysis of Risk Factors for Development of Liver Cirrhosis in Chronic Hepatitis B Patients. *Global Journal of Infectious Diseases and Clinical Research*, **4**: 004–006.

- Castéra, L., Le Bail, B., Roudot-Thoraval, F., Bernard, P.-H., Foucher, J., Merrouche, W., dkk., 2009. Early Detection in Routine Clinical Practice of Cirrhosis and Oesophageal Varices in Chronic Hepatitis C: Comparison of Transient Elastography (FibroScan) with Standard Laboratory Tests and Non-Invasive Scores. *Journal of Hepatology*, **50**: 59–68.
- Cheney, C.P., M. Goldberg, E., dan Chopra, S., 2012. Cirrhosis and Portal Hypertension: An Overview, dalam: Friedman, L.S. dan Keeffe, E.B. (Editor), *Handbook of Liver Disease*. Elsevier, Philadelphia, PA, hal. 136–150.
- Chow, S.-C., Wang, H., dan Shao, J., 2007. *Sample Size Calculations in Clinical Research, Second Edition*, 2nd edition. ed. Chapman and Hall/CRC, Boca Raton.
- Clarke, A.T., Johnson, P.C.D., Hall, G.C., Ford, I., dan Mills, P.R., 2016. High Dose Atorvastatin Associated with Increased Risk of Significant Hepatotoxicity in Comparison to Simvastatin in UK GPRD Cohort. *PloS One*, **11**: e0151587.
- Cohen, D.E., Anania, F.A., dan Chalasani, N., 2006. An Assessment of Statin Safety by Hepatologists. *The American Journal of Cardiology*, , Report of the National Lipid Association’s Statin Safety Task Force **97**: S77–S81.
- Dahlan, M.S., 2010. *Besar Sampel Dan Cara Pengambilan Sampel Dalam Penelitian Kedokteran Dan Kesehatan*. Salemba Medika, Jakarta.
- Davies, J.T., Delfino, S.F., Feinberg, C.E., Johnson, M.F., Nappi, V.L., Olinger, J.T., dkk., 2016. Current and Emerging Uses of Statins in Clinical Therapeutics: A Review. *Lipid Insights*, **9**: 13–29.
- Durand, F. dan Valla, D., 2005. Assessment of The Prognosis of Cirrhosis: Child–Pugh Versus MELD. *Journal of Hepatology*, **42**: S100–S107.
- Elwan, N., Salah, R., Hamisa, M., Shady, E., Hawash, N., dan Abd-Elsalam, S., 2018. Evaluation of Portal Pressure by Doppler Ultrasound in Patients with Cirrhosis Before and After Simvastatin Administration - A Randomized Controlled Trial. *F1000Research*, **7**: 256.
- Feverly, J., 2008. Bilirubin in Clinical Practice: A Review. *Liver International*, **28**: 592–605.
- Garcia-Compean, D., Jaquez-Quintana, J.O., Gonzalez-Gonzalez, J.A., dan Maldonado-Garza, H., 2009. Liver Cirrhosis and Diabetes: Risk Factors, Pathophysiology, Clinical Implications and Management. *World Journal of Gastroenterology : WJG*, **15**: 280–288.

- Garcia-Tsao, G., 2018. Ascites, dalam: Dooley, J.S., Lok, A.S.F., Garcia-Tsao, G., dan Pinzani, M. (Editor), *Sherlock's Diseases of the Liver and Biliary System*. John Wiley & Sons Ltd, Oxford, UK, hal. 127–150.
- GBD 2017 Cirrhosis Collaborators, 2020. The Global, Regional, and National Burden of Cirrhosis by Cause in 195 Countries and Territories, 1990–2017: a Systematic Analysis for The Global Burden of Disease Study 2017 - The Lancet Gastroenterology & Hepatology. *Lancet Gastroenterology & Hepatology*, **5**: 245–266.
- Gordon, F.D., 2012. Ascites. *Clinics in Liver Disease*, **16**: 285–299.
- Gu, Y., Yang, X., Liang, H., dan Li, D., 2019. Comprehensive Evaluation of Effects and Safety of Statin on The Progression of Liver Cirrhosis: a Systematic Review and Meta-Analysis. *BMC Gastroenterology*, **19**: 231.
- Ha, C.-E., Ha, J.-S., Theriault, A.G., dan Bhagavan, N.V., 2009. Effects of Statins on The Secretion of Human Serum Albumin in Cultured HepG2 Cells. *Journal of Biomedical Science*, **16**: 32.
- Hall, P. dan Cash, J., 2012. What is the Real Function of the Liver 'Function' Tests? *The Ulster Medical Journal*, **81**: 30–36.
- Hammer, G. dan McPhee, S., 2018. *Pathophysiology of Disease: An Introduction to Clinical Medicine 8E*, 8th edition. ed. McGraw-Hill Education / Medical, New York, N.Y.
- Hou, W. dan Sanyal, A.J., 2009. Ascites: Diagnosis and Management. *The Medical Clinics of North America*, **93**: 801–817, vii.
- Husin, A., 2016. 'Pengaruh Simvastatin Terhadap Kadar Nitrite Oxide dan Gastropati Hipertensi Portal pada Pasien Sirosis Hepatis', , *Thesis*, . UNS (Sebelas Maret University), Surakarta.
- Jepsen, P., 2014. Comorbidity in Cirrhosis. *World Journal of Gastroenterology*, **20**: 7223–7230.
- Jepsen, P., Vilstrup, H., Andersen, P.K., Lash, T.L., dan Sørensen, H.T., 2008. Comorbidity and Survival of Danish Cirrhosis Patients: a Nationwide Population-Based Cohort Study. *Hepatology (Baltimore, Md.)*, **48**: 214–220.
- Johnston, D.E., 1999. Special Considerations in Interpreting Liver Function Tests. *American Family Physician*, **59**: 2223.
- Kadikoylu, G., Yukselen, V., Yavasoglu, I., dan Bolaman, Z., 2003. Hemostatic Effects of Atorvastatin Versus Simvastatin. *The Annals of Pharmacotherapy*, **37**: 478–484.

- Kalaitzakis, E., Rosengren, A., Skommevik, T., dan Björnsson, E., 2010. Coronary Artery Disease in Patients with Liver Cirrhosis. *Digestive Diseases and Sciences*, **55**: 467–475.
- Kementerian Kesehatan RI, 2011. Pedoman Interpretasi Data Klinik.
- Kisseleva, T. dan Brenner, D.A., 2008. Mechanisms of Fibrogenesis. *Experimental Biology and Medicine (Maywood, N.J.)*, **233**: 109–122.
- Koffas, A. dan Kennedy, P., 2019. Liver Disease, dalam: Whittlesea, C. dan Hodson, K. (Editor), *Clinical Pharmacy and Therapeutics*. Elsevier, Inggris, hal. 258–277.
- Kumar, S., Grace, N.D., dan Qamar, A.A., 2014. Statin Use in Patients with Cirrhosis: A Retrospective Cohort Study. *Digestive Diseases and Sciences*, **59**: 1958–1965.
- Kwo, P.Y., Cohen, S.M., dan Lim, J.K., 2017. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. *The American Journal of Gastroenterology*, **112**: 18–35.
- Laroux, F.S., Lefer, D.J., Kawachi, S., Scalia, R., Cockrell, A.S., Gray, L., dkk., 2000. Role of Nitric Oxide in The Regulation of Acute and Chronic Inflammation. *Antioxidants & Redox Signaling*, **2**: 391–396.
- Mansoor, N., M. Ali, Y., Manzar, Z., Hussain, T., dan Ali, N., 2005. The Value of Clinical Signs in Diagnosis of Cirrhosis. *Pakistan Journal of Medical Sciences*, **21**: .
- Mansour, D. dan McPherson, S., 2018. Management of Decompensated Cirrhosis. *Clinical Medicine*, **18**: s60–s65.
- Maron, D.J., Fazio, S., dan Linton, M.F., 2000. Current Perspectives on Statins. *Circulation*, **101**: 207–213.
- Maruyama, H. dan Yokosuka, O., 2012. Pathophysiology of Portal Hypertension and Esophageal Varices. *International Journal of Hepatology*, **2012**: .
- Mason, J.C., 2003. Statins and Their Role in Vascular Protection. *Clinical Science*, **105**: 251–266.
- McCormick, P.A. dan Jalan, R., 2018. Hepatic Cirrhosis, dalam: Dooley, J.S., Lok, A.S.F., Garcia-Tsao, G., dan Pinzani, M. (Editor), *Sherlock's Diseases of the Liver and Biliary System*. John Wiley & Sons Ltd, Oxford, UK, hal. 107–126.
- Méndez-Sánchez, N., Vítek, L., Aguilar-Olivos, N.E., dan Uribe, M., 2017. Bilirubin as a Biomarker in Liver Disease, dalam: Patel, V.B. dan Preedy,

- V.R. (Editor), *Biomarkers in Liver Disease, Biomarkers in Disease: Methods, Discoveries and Applications*. Springer Netherlands, Dordrecht, hal. 281–304.
- Møller, S. dan Bernardi, M., 2013. Interactions of The Heart and The Liver. *European Heart Journal*, **34**: 2804–2811.
- Morali, G.A., Sniderman, K.W., Deitel, K.M., Tobe, S., Witt-Sullivan, H., Simon, M., dkk., 1992. Is Sinusoidal Portal Hypertension a Necessary Factor for The Development of Hepatic Ascites? *Journal of Hepatology*, **16**: 249–250.
- Morgan, M.Y., 2018. Hepatic Encephalopathy in Patients with Cirrhosis, dalam: Dooley, J.S., Lok, A.S.F., Garcia-Tsao, G., dan Pinzani, M. (Editor), *Sherlock's Diseases of the Liver and Biliary System*. John Wiley & Sons Ltd, Oxford, UK, hal. 151–179.
- Narulita, N., 2018. 'Perbedaan Perubahan Child Pugh Score Pada Penderita Sirosis Hati yang Diterapi dengan Simvastatin 20 mg Dibandingkan dengan Simvastatin 10 mg', . Universitas Gadjah Mada, Yogyakarta.
- Nasta, P., 2011. “Immune Activation, Aging and Gender” and Progression of Liver Disease. *Acta Bio-Medica: Atenei Parmensis*, **82**: 115–123.
- Ong, K.L., Wu, B.J., Cheung, B.M.Y., Barter, P.J., dan Rye, K.-A., 2011. Association of Lower Total Bilirubin Level with Statin Usage: The United States National Health and Nutrition Examination Survey 1999-2008. *Atherosclerosis*, **219**: 728–733.
- Onofrei, M.D., Butler, K.L., Fuke, D.C., dan Miller, H.B., 2008. Safety of Statin Therapy in Patients with Preexisting Liver Disease. *Pharmacotherapy*, **28**: 522–529.
- Patch, D. dan Dagher, L., 2001. Acute Variceal Bleeding: General Management. *World Journal of Gastroenterology*, **7**: 466–475.
- Prabowo, N.A., 2016. 'Pengaruh Simvastatin Terhadap Kadar Transforming Growth Factor  $\beta$ 1, Skor Fibroscan dan Skor Aspartat Transaminase to Platelet Index pada Pasien Sirosis Hati', , *Thesis*, . UNS (Sebelas Maret University), Surakarta.
- Prakash, R.K. dan Mullen, K.D., 2012. Hepatic Encephalopathy, dalam: S. Friedman, L. dan B. Keefe, E. (Editor), *Handbook of Liver Disease*. Elsevier, Philadelphia, PA, hal. 136–150.
- PubChem, 2005. 'Simvastatin', *PubChem*. URL: <https://pubchem.ncbi.nlm.nih.gov/compound/54454> (diakses tanggal 12/6/2021).

- Pugh, R.N., Murray-Lyon, I.M., Dawson, J.L., Pietroni, M.C., dan Williams, R., 1973. Transection of The Oesophagus for Bleeding Oesophageal Varices. *The British Journal of Surgery*, **60**: 646–649.
- Rizzetto, M., 2012. Treatment of Hepatitis B Virus Cirrhosis. *Hepatitis Monthly*, **12**: 309–311.
- Rockey, D.C., Caldwell, S.H., Goodman, Z.D., Nelson, R.C., dan Smith, A.D., 2009. Liver Biopsy. *Hepatology*, **49**: 1017–1044.
- Russo, M.W. dan Jacobson, I.M., 2004. How to Use Statins in Patients with Chronic Liver Disease. *Cleveland Clinic Journal of Medicine*, **71**: 58–62.
- Ryan, L., 2019. Portal Hypertension and Cirrhosis, dalam: Chisholm-Burns, M., Schwinghammer, T., Malone, P., Kolesar, J., Lee, K.C., dan Bookstaver, P.B. (Editor), *Pharmacotherapy Principles and Practice, Fifth Edition*. McGraw-Hill Education / Medical, New York, hal. 357–369.
- Sadowitz, B., Maier, K., dan Gahtan, V., 2010. Basic Science Review: Statin Therapy-Part I: The Pleiotropic Effects of Statins in Cardiovascular Disease. *Vascular and Endovascular Surgery*, **44**: 241–251.
- Sandvik, L., Erikssen, J., Mowinckel, P., dan Rødland, E.A., 1996. A Method for Determining The Size of Internal Pilot Studies. *Statistics in medicine*, **15**: 1587–1590.
- Schuppan, D. dan Afdhal, N.H., 2008. Liver Cirrhosis. *Lancet (London, England)*, **371**: 838–851.
- Schwartz, C.R. dan Garrison, M.W., 2012. Interpretation of Clinical Laboratory Test, dalam: Alldredge, B.K., Corelli, R.L., Ernst, M.E., Guglielmo, B.J., dan Jacobson, P.A. (Editor), *Koda-Kimble & Young's Applied Therapeutics: The Clinical Use of Drugs*. Lippincott Williams & Wilkins, Philadelphia.
- Shikdar, S., Vashisht, R., dan Bhattacharya, P.T., 2021. *International Normalized Ratio (INR)*, StatPearls [Internet]. StatPearls Publishing.
- Siederdisen, C.H. zu dan Cornberg, M., 2016. Management of HBV and HBV/HDV-Associated Liver Cirrhosis. *Visceral Medicine*, **32**: 86–94.
- Stancu, C. dan Sima, A., 2001. Statins: Mechanism of Action and Effects. *Journal of Cellular and Molecular Medicine*, **5**: 378–387.
- Stone, N.J., Robinson, J.G., Lichtenstein, A.H., Bairey Merz, C.N., Blum, C.B., Eckel, R.H., dkk., 2014. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. *Circulation*, **129**: S1–S45.



- Szabó, M., Veres, Z., Bátaí-Konczos, A., Kékesi, O., Kis, E., Szabó, K., dkk., 2014. Statins Alter The Hepatobiliary Transport of Unconjugated and Conjugated Bilirubin in Sandwich-Cultured Rat Hepatocytes. *Toxicology in vitro: an international journal published in association with BIBRA*, **28**: 1136–1143.
- Todd, P.A. dan Goa, K.L., 1990. Simvastatin. *Drugs*, **40**: 583–607.
- Undas, A., Brummel-Ziedins, K.E., dan Mann, K.G., 2005. Statins and Blood Coagulation. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **25**: 287–294.
- Vilstrup, H., Amodio, P., Bajaj, J., Cordoba, J., Ferenci, P., Mullen, K.D., dkk., 2014. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by The American Association for The Study of Liver Diseases and The European Association for The Study of The Liver. *Hepatology*, **60**: 715–735.
- Wang, C.-Y., Liu, P.-Y., dan Liao, J.K., 2008. Pleiotropic Effects of Statin Therapy. *Trends in molecular medicine*, **14**: 37–44.